| Market Cap | 10.56M | P/E | 12.88 | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -2.63M | Forward P/E | 1.58 | EPS next Y | - | 50D Avg Chg | 8.00% |
| Sales | 20.93M | PEG | - | EPS past 5Y | 45.57% | 200D Avg Chg | 17.00% |
| Dividend | N/A | Price/Book | 0.51 | EPS next 5Y | 5.00% | 52W High Chg | -5.00% |
| Recommedations | - | Quick Ratio | 1.21 | Shares Outstanding | 10.44M | 52W Low Chg | 49.00% |
| Insider Own | 26.68% | ROA | -5.63% | Shares Float | 5.24M | Beta | 0.90 |
| Inst Own | 23.10% | ROE | -12.90% | Shares Shorted/Prior | 15.08K/15.37K | Price | 1.03 |
| Gross Margin | 61.41% | Profit Margin | -12.56% | Avg. Volume | 4,053 | Target Price | - |
| Oper. Margin | -21.65% | Earnings Date | Nov 19 | Volume | 30,508 | Change | -0.96% |
Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing Sodium Nitroprusside injection, and Generic ANDA 2 and 3 for acute cardiology; and TARDOCAL, to treat neurological indications. It offers products through retail and mail order pharmacies. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada.